Abstract
Achieving good gtycaemic control is an important part of the treatment strategy to minimise vascular complications in diabetes. An expanding range of differently acting oral antidiabetic agents provides new choices for type 2 patients. This review considers the attributes and limitations of these agents, and their positioning in the treatment process.
| Original language | English |
|---|---|
| Pages (from-to) | 128-136 |
| Number of pages | 9 |
| Journal | British Journal of Cardiology |
| Volume | 10 |
| Issue number | 2 |
| Publication status | Published - Mar 2003 |
Keywords
- Acarbose
- Antidiabetic drugs
- Insul in
- Meglitinides
- Metabolic syndrome
- Metformin
- Sulphonylureas
- Thiazolidinediones
- Type 2 diabetes